Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK

PharmacoEconomics

Volumn 22, Issue 5, 2004, Pages 311-319

  Lenox Smith, Alan ^a   Conway, Pete ^a   Knight, Chris ^b  

^a Wyeth   (United Kingdom)

^b Heron Evidence Development Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; PAROXETINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; HEALTH CARE COST; HUMAN; INTERVIEW; MAJOR DEPRESSION; META ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIST; REMISSION; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; DEPRESSIVE DISORDER; ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HUMANS; TREATMENT OUTCOME;

EID: 2142814312     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422050-00005     Document Type: Article

References (17)

1. Jenkins R, Lewis G, Bebbington P, et al. The National Psychiatric Morbidity Surveys of Great Britain - initial findings from the Household Survey. Psychol Med 1997; 27: 775-89
2. Psychiatric morbidity among adults living in private households, 2000 [online]. http://www.statistics.gov.uk/downloads/ theme_health/psychmorb.pdf [Accessed 2004 Jan 13]
3. Lepine J-P, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clinical Psychopharmacol 1997; 12: 19-29
4. IMS figures from British Pharmaceutical Index: MAT 2001 (database). London: IMS, 2001
5. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000 Aug; 18 (2): 143-8
6. Rush AJ, Trivedi M. Treating depression to remission. Psychiatric Annals 1995; 25: 704-9
7. Paykel ES, Raman R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171-80
8. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992; 149: 1046-52
9. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178 (3): 234-41
10. Beasley Jr CM, Sayler ME, Potvin JH, et al. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol 1993; 8: 143-9
11. Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999; 21 (2): 296-308
12. Office of National Statistics. Consumer price indices, July 2002 [online]. Available from URL: http://www.statistics.gov.uk/ pdfdir/cpi0802.pdf [Accessed 2003 Jan 13]
13. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7 (3-4): 191-5
14. Din-link data. Woking, Surrey: CompuFile Ltd, MAT, 2002 Jun
15. Anderson I. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Dis; 58 (2000) 19-36
16. Lenox-Smith AJ, Schaeffer P, Reynolds A, et al. A double-blind trial of venlafaxine XR vs citalopram in patients with treatment-resistant depression. Poster presented at British Association for Psychopharmacology; 2001 Jul 21-24; Harrogate
17. Mehtonen O-P, editor. Randomised, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000; 61: 95-100